Sugi Predict

Sugi Predict / Compounds / SCHEMBL1809516

SCHEMBL1809516

SCHEMBL1809516

CCOC(=O)c1c[c]ccc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.49
▸ HSD17B2 P37059 1/20 0.45
▸ LMNA P02545 4/20 0.44
▸ MAPT P10636 3/20 0.44
▸ CDC25B P30305 1/20 0.44
▸ DPP4 P27487 3/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ HPGD P15428 3/20 0.43
▸ HSD17B10 Q99714 1/20 0.42
▸ GAA P10253 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CA12 O43570 3/20 0.41
▸ CA2 P00918 3/20 0.41
▸ CA7 P43166 3/20 0.41
▸ CA9 Q16790 3/20 0.41
▸ CA14 Q9ULX7 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810786 0.87 TSHR (0.49) TSHRLMNAMAPTCDC25BALDH1A1
SCHEMBL9827992 0.87 TSHR (0.49) TSHRHSD17B2LMNAMAPTCDC25B
SCHEMBL129924 0.83 TSHR (0.60) TSHRLMNAMAPTCDC25BALDH1A1
SCHEMBL2443988 0.83 GAA (0.45) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL7499134 0.81 TSHR (0.53) TSHRLMNACDC25BALDH1A1KDM4E
SCHEMBL971903 0.80 CA12 (0.56) TSHRMAPTALDH1A1HSD17B10CA12
SCHEMBL1809860 0.80 TSHR (0.49) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL4738309 0.79 CYP4F2 (0.51) TSHRALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL27999935 0.79 TSHR (0.50) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL19212264 0.79 TSHR (0.50) TSHRLMNAALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311729-A1 Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors CAPRARO HANS-GEORG 2010-12-09 — — US claimed
EP-2155202-A2 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS Novartis Ag (CH) 2010-02-24 — — EP claimed
WO-2008138889-A2 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS NOVARTIS AG (CH) 2008-11-20 — — WO claimed
US-9318706-B2 Laminated structure, method for producing same, and electronic element comprising same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-04-19 — — US disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 — — CN disclosed
US-8895675-B2 Block copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-11-25 — — US disclosed
US-20110177312-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-21 — — US disclosed
CN-1809570-B [1,2,4] triazolo [1,5-a ] pyrimidin-2-ylurea derivatives and uses thereof NIPPON KAYAKU KK 2011-06-22 — — CN disclosed
EP-2325914-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME Sumitomo Chemical Company, Limited (JP) 2011-05-25 — — EP disclosed
US-20100311729-A1 Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors CAPRARO HANS-GEORG 2010-12-09 — — US disclosed
US-20100219399-A1 BLOCK COPOLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-02 — — US disclosed
US-20100176377-A1 Polymeric compound and polymeric electroluminescence element using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-15 — — US disclosed
CN-101472902-A Novel piperazine compounds and their use as HCV polymerase inhibitors JAPAN TOBACCO INC (JP) 2009-07-01 — — CN disclosed
US-20080293939-A1 QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS CULSHAW ANDREW JAMES 2008-11-27 — — US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 — — CN disclosed
CN-1090184-C Heterocyclic compounds FUJISAWA PHARMACEUTICAL CO (JP) 2002-09-04 — — CN disclosed
CN-1046714-C Diaryl oxazole derivative and its preparation method, application and pharmaceutical composition FUJISAWA PHARMACEUTICAL CO (JP) 1999-11-24 — — CN disclosed
CN-1229795-A Heterocyclic compounds FUJISAWA PHARMACEUTICAL CO (JP) 1999-09-29 — — CN disclosed
CN-1138328-A Heterocyclic compounds FUJISAWA PHARMACEUTICAL CO (JP) 1996-12-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293939-A1 QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS OPRK1, OPRL1, TRPV1 TSHR 2413/4885HSD17B2 3701/4885LMNA 3188/4885
US-20110177312-A1 LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME EPCAM, ITGA1, ITGB1 TSHR 4526/4885HSD17B2 3572/4885LMNA 331/4885
US-20100311729-A1 Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors PI4KA, PIP5K1B, PIP4K2A TSHR 3280/4885HSD17B2 1946/4885LMNA 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.